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Supplementary Table 
 
ATP1A2 mutations identified in migraine, as published in the literature until May 2016. For each mutation the characteristic clinical 
phenotype is provided with the respective reference (FHM - familial hemiplegic migraine, SHM - sporadic hemiplegic migraine, MA/MO - 
migraine with/without aura, BM - basilar migraine), the location of the mutation position within the Na+,K+-ATPase structure, reference(s) reporting 
functional tests (as available) and a summary of the findings obtained from these studies. The listed references were identified with searches for the 
keyword combination “[migraine] and ([ATP1A2] or [ATPase])” in title or abstract. 
ATP1A2 
allelic 
variant 
mutation 
type phenotype 
localisation in 
3D structure 
reference 
(genetics) 
reference 
(functional test) effect(s) on function (if any) 
Y9N missense mutation SHM A domain 
(Gallanti et al., 2011) 
(Thomsen et al., 
2008) 
(Tonelli et al., 2007) 
(Swarts et al., 2013)
Sf9 cells: normal protein expression, ouabain binding 
and ouabain affinity; apparent K+ and Na+ affinity, 
ATP affinity and turnover as WT in ATPase assay 
K35del  deletion FHM & epilepsy A domain (Riant et al., 2010)   
R51H missense mutation MO A domain (Castro et al., 2008a) (Swarts et al., 2013)
Sf9 cells: normal protein expression, ouabain binding 
and ouabain affinity; apparent K+ and Na+ affinity, 
ATP affinity and turnover as WT in ATPase assay 
R65W missense mutation FHM A domain 
(Gallanti et al., 2011) 
(Tonelli et al., 2007)   
E120A missense mutation SHM 
TM1-2 loop, 
ouabain binding 
region 
(de Vries et al., 2007) (de Vries et al., 2007) 
HeLa cells: reduction of survival under ouabain 
challenge, normal protein level 
V138A missense mutation FHM TM2 
(Thomsen et al., 
2007) (Schack et al., 2012)
COS-1 cells (membrane fractions): ATPase assays: 
decreased ouabain affinity and turnover rate, apparent 
K+ affinity as WT, increased ATP affinity, reduced 
vanadate sensitivity; Phosphorylation assays: reduced 
Na+ affinity and phosphoenzyme level, reduced Vmax 
E174K missense mutation MO A domain (Todt et al., 2005) 
(Todt et al., 2005) 
(Swarts et al., 2013)
X. laevis oocytes: ATPase activity identical to WT, 
electrophysiology: pump currents identical to WT, 
normal overall protein level 
Sf9 cells: normal protein expression, ouabain binding 
and ouabain affinity; reduced ATPase activity with 
similar ATP affinity and apparent K+ and Na+ 
affinity, ATP affinity, reduced turnover in ATPase 
assay compared to WT 
V191M missense mutation 
migraine & 
sensorineural 
hearing loss 
A domain (Oh et al., 2015) (Oh et al., 2015) 
Protein purified from Sf9 cells: no reduction in 
ouabain binding, no change in apparent Na+ and K+ 
affinity of ATPase activity 
Electrophysiology on X. laevis oocytes: Pump 
currents, K+ and voltage dependence of pump 
currents and voltage dependence of ouabain-sensitive 
Na+/Na+ exchange currents identical to WT 
R202Q missense mutation FHM A domain 
(Thomsen et al., 
2007) (Schack et al., 2012)
COS-1 cells (membrane fractions): ATPase assays: 
ouabain affinity as WT, slightly reduced turnover 
rate, apparent K+ affinity as WT, slightly increased 
ATP affinity, reduced vanadate sensitivity; 
Phosphorylation assays: Na+ affinity and 
phosphoenzyme level as WT 
S220L missense mutation FHM 
A domain, TGES
motif (Roth et al., 2014)   
T263M missense mutation FHM A domain (Riant et al., 2005) 
(Tavraz et al., 2008)
(Schack et al., 2012)
X. laevis oocytes: No pump currents, strongly 
reduced Rb+ uptake, normal overall and plasma 
membrane protein level 
COS-1 cells (membrane fractions): ATPase assays: 
strongly decreased ouabain affinity, reduced turnover 
rate, increased apparent K+ affinity, increased ATP 
affinity, reduced vanadate sensitivity; 
Phosphorylation assays: slightly reduced Na+ affinity 
and phosphoenzyme level 
I286T missense mutation 
FHM 
(compound 
heterozygous 
with T415M) 
TM3 (Vanmolkot et al., 2007) 
(Vanmolkot et al., 
2007) 
HeLa cells: reduction of survival under ouabain 
challenge, normal protein level 
G301R missense mutation 
FHM, seizures, 
cerebellar signs TM3 
(Spadaro et al., 2004) 
(Santoro et al., 2011) 
(Santoro et al., 2011)
(Tavraz et al., 2009)
HeLa cells: reduction of survival under ouabain 
challenge, no plasma membrane expression (c-myc 
epitope reactivity), no protein detectable in Western 
blot  
X. laevis oocytes: No pump current, strongly reduced 
Rb+ uptake, total and plasma membrane protein level 
as WT 
F305del deletion SHM TM3 (Riant et al., 2010)   
V338A missense mutation SHM TM4-5 loop (Riant et al., 2010)   
c.1025T>C 
L342P 
missense 
mutation FHM P domain (Asghar et al., 2012)   
T345A missense mutation FHM P domain (Kaunisto et al., 2004)
(Segall et al., 2004) 
(Weigand et al., 
2014) 
(Schack et al., 2012)
HeLa cells: normal expression and cell growth under 
ouabain challenge, normal catalytic turnover (Vmax),  
reduced apparent K+, ATP affinity and vanadate 
sensitivity (ATPase activity tests), reduced affinity in 
86Rb+ uptake assay; tests performed on rat ATP1A2 
Sf9 cells: normal protein expression and slightly 
increased ouabain binding compared to WT, slightly 
decreased Na+ and K+ affinity in ATPase assay 
COS-1 cells (membrane fractions): ATPase assays: 
decreased ouabain affinity and turnover rate, 
decreased apparent K+ affinity as WT, increased ATP 
affinity, decreased vanadate sensitivity; 
Phosphorylation assays: reduced Na+ affinity and 
phosphoenzyme level, strongly reduced Vmax 
V362E missense mutation FHM P domain (Castro et al., 2008b) (Castro et al., 2008b)
HeLa cells: strongly reduced cell survival under 
ouabain challenge, normal protein level 
T364M missense mutation 
SHM, FHM, 
aphasia P domain 
(Riant et al., 2005) 
(Castro et al., 2007) 
(Toldo et al., 2010) 
  
T368K missense mutation SHM TM4-5 loop (Riant et al., 2010)   
T376M missense mutation FHM P domain 
(Riant et al., 2005) 
(Castro et al., 2007) (Tavraz et al., 2008)
X. laevis oocytes: No pump currents, strongly 
reduced Rb+ uptake, normal overall and plasma 
membrane protein level 
T378N missense mutation 
FHM 
AHC P domain 
(Bassi et al., 2004) 
(Swoboda et al., 
2004) 
(Bassi et al., 2004) 
HeLa cells: strongly reduced cell survival under 
ouabain challenge, normal in vitro protein translation 
and normal cellular expression pattern (c-myc 
reactivity), protein detected normally in microsomal 
and cytosolic membrane fractions 
R383H missense mutation SHM N domain 
(Jurkat-Rott et al., 
2004) (Tavraz et al., 2008)
X. laevis oocytes: Reduced pump currents, reduced 
turnover rate, but apparent K+ affinity from pump 
currents as WT, normal overall and plasma 
membrane protein level; voltage dependence of 
ouabain-sensitive Na+/Na+ exchange currents 
positively shifted compared to WT (↔increased 
apparent affinity for extracellular Na+), kinetics of 
Na+/Na+ exchange currents similar to WT 
T415M missense mutation 
FHM 
(compound 
heterozygous 
with I286T) 
N domain (Vanmolkot et al., 2007) 
(Vanmolkot et al., 
2007) 
HeLa cells: no survival under ouabain challenge, 
normal protein level 
E492K missense mutation SHM N domain (de Vries et al., 2007)
(de Vries et al., 
2007) 
HeLa cells: reduction of survival under ouabain 
challenge, normal protein level 
R510S polymorphism ? N domain (Thomsen et al., 2007)   
C515Y missense mutation MA N domain (Todt et al., 2005) (Todt et al., 2005) 
X. laevis oocytes: ATPase activity strongly reduced, 
normal overall protein level; electrophysiology: 
strongly reduced pump currents 
R548H missense mutation BM/MA N domain 
(Ambrosini et al., 
2005) (Swarts et al., 2013)
Sf9 cells: normal protein expression, slightly reduced 
ouabain binding with normal ouabain affinity; 
increased apparent K+ and decreased apparent Na+ 
affinity, strongly reduced ATPase activity with 
similar ATP affinity and strongly reduced turnover in 
ATPase assay compared to WT 
R548C missense mutation FHM P domain (Lebas et al., 2008) (Swarts et al., 2013)
Sf9 cells: normal protein expression, similar ouabain 
binding and ouabain affinity; increased apparent K+ 
and decreased apparent Na+ affinity, strongly reduced 
ATPase activity with similar ATP affinity and 
strongly reduced turnover in ATPase assay compared 
to WT 
I589T missense mutation 
Atypical AHC 
& generalized 
seizures 
P domain (Al-Bulushi et al., 2014)   
R593W missense mutation FHM P domain 
(Vanmolkot et al., 
2006a) 
(Vanmolkot et al., 
2006a) 
(Schack et al., 2012)
HeLa cells: strongly reduced survival upon ouabain 
challenge, normal protein level 
COS-1 cells (membrane fractions): ATPase assays: 
strongly decreased ouabain affinity and turnover rate, 
increased apparent K+ affinity, increased ATP 
affinity, strongly reduced vanadate sensitivity; 
Phosphorylation assays: reduced Na+ affinity, 
strongly reduced phosphoenzyme level and Vmax 
V600A missense mutation FHM TM4-5 loop 
(De Cunto et al., 
2012)   
R604P missense mutation SHM TM4-5 loop (Riant et al., 2010)   
A606T missense mutation 
FHM, 
FHM 
&transient 
learning 
disorder 
P domain 
(Riant et al., 2005) 
(Jen et al., 2007) 
(Carreño et al., 2013) 
(Podestà et al., 2011) 
(Jen et al., 2007) 
(Tavraz et al., 2008)
HeLa cells: strongly reduced survival upon ouabain 
challenge 
X. laevis oocytes: reduced pump currents, reduced 
turnover rate, normal overall and plasma membrane 
protein level, reduced apparent affinity for K+ of 
pump currents at all voltages tested, strong positive 
shift in voltage dependence of ouabain-sensitive 
Na+/Na+ exchange currents shifted compared to WT 
(↔decreased apparent affinity for extracellular Na+), 
rate constants from Na+/Na+ exchange currents 
increased at negative potentials compared to WT 
G615R missense mutation 
 
FHM 
SHM 
 
P domain 
(Vanmolkot et al., 
2006b) 
(Riant et al., 2010) 
(Vanmolkot et al., 
2006b) 
HeLa cells: strongly reduced survival upon ouabain 
challenge, normal protein level 
G615E missense mutation 
 
SHM 
 
P domain (Riant et al., 2010)   
V628M missense mutation FHM P domain 
(Vanmolkot et al., 
2006a) 
(Vanmolkot et al., 
2006a) 
(Schack et al., 2012)
HeLa cells: strongly reduced survival upon ouabain 
challenge, normal protein level 
COS-1 cells (membrane fractions): ATPase assays: 
decreased ouabain affinity, strongly reduced turnover 
rate, increased apparent K+ affinity, slightly increased 
ATP affinity, strongly reduced vanadate sensitivity; 
Phosphorylation assays: reduced Na+ affinity, 
strongly reduced phosphoenzyme level and Vmax 
R689Q missense mutation FHM & BFIC P domain 
(Vanmolkot et al., 
2003) 
(Segall et al., 2005) 
(Capendeguy and 
Horisberger, 2004) 
HeLa cells: reduced cell survival under ouabain 
challenge; reduced vanadate sensitivity, unchanged 
apparent ATP affinity, reduced catalytic turnover 
(Vmax from ATPase activity vs. oligomycin- 
stabilized phosphoenzyme level), normal apparent 
Na+ and reduced apparent K+ affinity in ATPase 
assays, but 5.6-fold increased protein level compared 
to WT; reduced apparent K+ affinity in 86Rb+ uptake 
assay; tests performed on rat ATP1A2 
X. laevis oocytes: protein expression similar to WT in 
pulse chase labeling experiment, reduced ouabain 
binding; homologous Bufo marinus α1 mutant: 
reduced palytoxin-induced current, no pump current 
E700K missense mutation FHM P domain (Pierelli et al., 2006) 
(Swarts et al., 2013) 
(Schack et al., 2012)
Sf9 cells: normal protein expression, strongly 
reduced ouabain binding with normal ouabain 
affinity; strongly reduced turnover in ATPase assay 
compared to WT 
COS-1 cells (membrane fractions): ATPase assays: 
increased ouabain affinity, reduced turnover rate, 
decreased apparent K+ affinity, increased ATP 
affinity, strongly reduced vanadate sensitivity; 
Phosphorylation assays: reduced Na+ affinity and 
slightly increased phosphoenzyme level, reduced 
Vmax 
C702Y missense mutation 
MA/MO & 
epilepsy P domain (Deprez et al., 2008) (Swarts et al., 2013)
Sf9 cells: normal protein expression, reduced ouabain 
binding with slightly increased ouabain affinity; 
apparent K+ and Na+ affinity as WT, reduced ATPase 
activity with decreased ATP affinity and reduced 
turnover in ATPase assay compared to WT 
V711L missense mutation FHM TM4-5 (Riant et al., 2010)   
G715R missense mutation SHM P domain 
(De Sanctis et al., 
2011)   
N717K missense mutation SHM P domain (Jen et al., 2007) (Jen et al., 2007) 
HeLa cells: strongly reduced survival under ouabain 
challenge 
D718N missense mutation FHM P domain 
(Jurkat-Rott et al., 
2004)   
A721T missense mutation 
SHM + MO, 
speech deficits TM4-5 (Riant et al., 2010)   
M731T missense mutation 
FHM, BFIC, 
psychotic aura P domain 
(Vanmolkot et al., 
2003) 
(Castro et al., 2007) 
(Barros et al., 2012) 
(Segall et al., 2004) 
(Segall et al., 2005) 
(Capendeguy and 
Horisberger, 2004) 
(Schack et al., 2012)
HeLa cells: normal cell survival under ouabain 
challenge; strongly reduced vanadate sensitivity, 
reduced apparent ATP affinity, strongly reduced 
catalytic turnover (Vmax from ATPase activity vs. 
oligomycin- stabilized phosphoenzyme level), normal 
apparent Na+ and reduced apparent K+ affinity in 
ATPase assays, but 5.6-fold increased protein level 
compared to WT; reduced apparent K+ affinity in 
86Rb+ uptake assay; tests performed on rat ATP1A2 
X. laevis oocytes: protein expression similar to WT in 
pulse chase labeling experiment, reduced ouabain 
binding; homologous Bufo marinus α1 mutant: 
palytoxin-induced current as WT, no pump current 
COS-1 cells (membrane fractions): ATPase assays: 
strongly reduced ouabain affinity and turnover rate, 
increased apparent K+ affinity, increased ATP 
affinity, strongly reduced vanadate sensitivity; 
Phosphorylation assays: strongly increased Na+ 
affinity, reduced phosphoenzyme level, strongly 
reduced Vmax 
M745I missense mutation SHM P domain 
(Thomsen et al., 
2008)   
c.2273G>C 
G758A 
missense 
mutation SHM TM5 (Aceves et al., 2013)   
R763H missense mutation FHM TM5 
(Jurkat-Rott et al., 
2004) (Tavraz et al., 2008)
X. laevis oocytes: reduced pump currents, reduced 
turnover rate, normal overall and plasma membrane 
protein level, increased apparent affinity for K+ of 
pump currents at all voltages tested, voltage 
dependence and kinetics of ouabain-sensitive 
Na+/Na+ exchange currents similar to WT 
R763C missense mutation FHM TM5 
(Thomsen et al., 
2007)   
L764P missense mutation FHM TM5 
(De Fusco et al., 
2003) 
(De Fusco et al., 
2003) 
(Capendeguy and 
Horisberger, 2004) 
(Koenderink et al., 
2005) 
COS7 cells: no cell survival under ouabain challenge, 
normal in vitro protein synthesis, physiological 
location of and mutant protein in the membrane 
fraction 
X. laevis oocytes: protein expression similar to WT in 
pulse chase labeling experiment, no ouabain binding; 
homologous Bufo marinus α1 mutant: reduced 
palytoxin-induced current, no pump current 
X. laevis oocytes: Plasma membrane expression in 
similar to WT, ouabain binding strongly reduced, 
ATPase activity strongly reduced (oocyte total 
membranes), Rb+ uptake strongly reduced; 
electrophysiology: strongly reduced pump currents 
Y775C missense mutation 
SHM + 
epilepsia 
(febrile 
seizures)  
TM5 (Riant et al., 2010)   
P786L missense mutation SHM TM5 (de Vries et al., 2007)
(de Vries et al., 
2007) 
(Swarts et al., 2013)
HeLa cells: no cell survival under ouabain challenge, 
normal protein level 
Sf9 cells: slightly reduced protein expression, no 
ouabain binding; no ATPase activity 
P796R missense mutation FHM TM5-6 loop 
(Jurkat-Rott et al., 
2004)   
P796S missense mutation FHM TM5-6 loop (Castro et al., 2008b) 
(Castro et al., 2008b)
(Weigand et al., 
2014) 
HeLa cells: strongly reduced cell survival under 
ouabain challenge, normal protein level 
Sf9 cells: normal protein expression, no ouabain 
binding, no ATPase activity 
E825K missense mutation 
FHM & febrile 
seizures TM6-7 loop (Carreño et al., 2013) 
(Carreño et al., 
2013) 
HeLa cells: strongly reduced cell survival under 
ouabain challenge, reduced protein level 
M829R missense mutation FHM TM6-7 loop (Riant et al., 2005) 
(Tavraz et al., 2008)
(Weigand et al., 
2014) 
X. laevis oocytes: slightly reduced pump currents, 
normal turnover rate, normal overall and plasma 
membrane protein level, apparent affinity for K+ of 
pump currents similar to WT, negative shift in 
voltage dependence of ouabain-sensitive Na+/Na+ 
exchange currents shifted compared to WT 
(↔decreased apparent affinity for extracellular Na+), 
rate constants from Na+/Na+ exchange currents 
increased at all potentials tested compared to WT 
Sf9 cells: normal protein expression, no ouabain 
binding, no ATPase activity 
R834Q missense mutation FHM TM6-7 loop (Riant et al., 2005) 
(Tavraz et al., 2008)
(Weigand et al., 
2014) 
(Schack et al., 2012)
X. laevis oocytes: reduced pump currents, strongly 
reduced turnover, normal overall and plasma 
membrane protein level, apparent affinity for K+ of 
pump currents as WT, positive shift in voltage 
dependence of ouabain-sensitive Na+/Na+ exchange 
currents shifted compared to WT (↔increased 
apparent affinity for extracellular Na+), rate constants 
from Na+/Na+ exchange currents increased at all 
potentials tested compared to WT 
Sf9 cells: normal protein expression, strongly 
reduced ouabain binding, strongly reduced ATPase 
activity, increased apparent K+ and decreased 
apparent Na+ affinity in ATPase assay 
COS-1 cells (membrane fractions): ATPase assays: 
strongly decreased ouabain affinity and turnover rate, 
increased apparent K+ affinity, increased ATP 
affinity, strongly reduced vanadate sensitivity; 
Phosphorylation assays: strongly reduced Na+ 
affinity, phosphoenzyme level and Vmax 
R834X non-sense mutation FHM TM6-7 loop (de Vries et al., 2007)
(de Vries et al., 
2007) 
(Weigand et al., 
2014) 
HeLa cells: no cell survival under ouabain challenge, 
normal protein level 
Sf9 cells: normal protein expression, no ouabain 
binding, no ATPase activity 
G855R missense mutation 
FHM & febrile 
seizures TM7 (de Vries et al., 2009)
(de Vries et al., 
2009) 
(Spiller and 
Friedrich, 2014) 
HeLa cells: no cell survival under ouabain challenge, 
normal protein level 
X. laevis oocytes: no pump currents, normal overall 
protein expression but strongly reduced plasma 
membrane protein 
G855V missense mutation SHM TM7 (Riant et al., 2010)    
G874S missense mutation 
FHM, epilepsy 
(GEFS+) TM7-8 loop (Costa et al., 2014)   
R879Q missense mutation SHM TM7-8 loop 
(Thomsen et al., 
2008) (Swarts et al., 2013)
Sf9 cells: normal protein expression, reduced ouabain 
binding and ouabain affinity; apparent K+ and Na+ 
affinity as WT, reduced ATPase activity with 
decreased ATP affinity and normal turnover in 
ATPase assay compared to WT 
R879W missense mutation SHM TM7-8 loop 
(Thomsen et al., 
2008) 
(Weigand et al., 
2014) 
Sf9 cells: normal protein expression, reduced ouabain 
binding, reduced ATPase activity, sligntly decreased 
apparent Na+ affinity and slightly increased apparent 
K+ affinity in ATPase assay 
I883L polymorphism ? TM7-8 loop (Jurkat-Rott et al., 2004) (Tavraz et al., 2009)
HEK293FT cells: plasma membrane protein level 
(biotinylation assay) as WT at 28 and 37 °C. 
W887R missense mutation FHM TM7-8 loop 
(De Fusco et al., 
2003) 
(De Fusco et al., 
2003) 
(Capendeguy and 
Horisberger, 2004) 
(Koenderink et al., 
2005) 
(Leo et al., 2011) 
COS7 cells: no cell survival under ouabain challenge, 
normal in vitro protein synthesis, physiological 
location of and mutant protein in the membrane 
fraction 
X. laevis oocytes: strongly reduced expression in 
pulse chase labeling experiment, no ouabain binding; 
homologous Bufo marinus α1 mutant: no palytoxin-
induced current, no pump current, suspicious K+-
induced outward current in the absence of external 
Na+ 
X. laevis oocytes: Plasma membrane expression 
similar to WT, ouabain binding strongly reduced, 
ATPase activity strongly reduced (oocyte total 
membranes), Rb+ uptake strongly reduced; 
electrophysiology: strongly reduced pump currents 
Transgenic mice: homozygous 
ATP1A2(W887R/W887R) mutants die shortly after 
birth, heterozygous ATP1A2(+/W887R) mutants 
show no apparent phenotype but enhanced 
susceptibility for CSD; no or strongly reduced 
ATP1A2 protein in homo- or heterozygous mutants 
brains, respectively 
HeLa cells: decreased W887R mutant protein; 
immunofluorescence: ER localisation dominant (no 
plasma membrane protein), pattern changed by 
proteasome inhibitors 
G900R missense mutation 
FHM & 
epilepsy TM7-8 loop (Deprez et al., 2008) 
(Spiller and 
Friedrich, 2014) 
(Swarts et al., 2013)
X. laevis oocytes: normal K+ and voltage dependence 
of pump currents, voltage dependence of ouabain-
sensitive Na+/Na+ exchange currents similar to WT, 
general increase in rate constants of Na+/Na+ 
exchange currents 
Sf9 cells: normal protein expression, strongly 
reduced ouabain binding with increased ouabain 
affinity; apparent K+ and Na+ affinity as WT, reduced 
ATPase activity with decreased ATP affinity and 
normal turnover in ATPase assay compared to WT 
E902K missense mutation FHM TM7-8, loop 
(Jurkat-Rott et al., 
2004) 
(Spiller and 
Friedrich, 2014) 
(Swarts et al., 2013)
X. laevis oocytes: normal pump currents with slightly 
increased apparent K+ affinity at positive potentials, 
voltage dependence of ouabain-sensitive Na+/Na+ 
exchange currents similar to WT, general increase in 
rate constants of Na+/Na+ exchange currents 
Sf9 cells: normal protein expression, strongly 
reduced ouabain binding and slightly increased  
ouabain affinity; slightly decreased apparent Na+ 
similar apparent K+ affinity, reduced ATPase activity 
with decreased ATP affinity and normal turnover in 
ATPase assay compared to WT 
R908Q missense mutation SHM, FHM TM7-8 loop 
(de Vries et al., 2007)
(Hermann et al., 
2013) 
(Roth et al., 2014) 
(de Vries et al., 
2007) 
(Tavraz et al., 2009)
HeLa cells: no survival under ouabain challenge 
X. laevis oocytes: reduced Rb+ uptake, reduced pump 
currents; K+ and voltage dependence of pump 
currents, kinetics and voltage dependence of ouabain-
sensitive Na+/Na+ exchange currents similar to WT; 
normal overall and reduced plasma membrane 
protein level 
H916L missense mutation 
FHM with 
prolonged aura TM8 (Iizuka et al., 2014)   
Q927P missense mutation 
FHM + 
epilepsy 
(generalized 
seizures) 
TM8 (Riant et al., 2010)   
del(K935-
S940)insI 
deletion & 
insertion FHM TM8-9 loop (Riant et al., 2005) 
(Tavraz et al., 2008)
(Weigand et al., 
2014) 
X. laevis oocytes: no pump currents, no Rb+ uptake, 
normal overall but strongly reduced plasma 
membrane protein level 
Sf9 cells: normal protein expression, no ouabain 
binding, no ATPase activity 
R937P missense mutation FHM TM8-9 loop (Riant et al., 2005) 
(Tavraz et al., 2008)
(Poulsen et al., 
2010) 
(Weigand et al., 
2014) 
X. laevis oocytes: no pump currents, strongly reduced 
Rb+ uptake, normal overall and plasma membrane 
protein level 
X. laevis oocytes: extreme negative shift of voltage 
dependence of ouabain-sensitive Na+/Na+ exchange 
currents (↔decreased apparent affinity for 
extracellular Na+), inverted voltage dependence of 
rate constants of Na+/Na+ exchange currents (high at 
positive, low at negative voltages), strongly 
augmented “leak” currents in the presence of 
extracellular Na+ 
Sf9 cells: normal protein expression, strongly 
reduced ouabain binding, no ATPase activity 
S940L Missense mutation 
FHM & 
pulmonary 
arterial 
hypertension 
TM9 (Montani et al., 2013)   
S966fs 
frameshift, 
premature 
Stop 
FHM TM9-10 loop (Riant et al., 2005) (Tavraz et al., 2008)this study 
X. laevis oocytes: no pump currents, no Rb+ uptake, 
normal overall protein expression but hardly any 
plasma membrane protein 
P979L missense mutation 
FHM, SHM & 
reversible 
cerebral 
vasoconstriction
TM9-10 loop 
(Jurkat-Rott et al., 
2004) 
(Hermann et al., 
2013) 
(Tavraz et al., 2008)
(Tavraz et al., 2008)
this work 
X. laevis oocytes: K+ and voltage dependence of 
pump currents, kinetics and voltage dependence of 
ouabain-sensitive Na+/Na+ exchange currents as WT; 
normal overall and plasma membrane protein level 
HEK293FT cells: overall and plasma membrane 
protein level (biotinylation assay) as WT at 28 °C, 
strongly reduced plasma membrane protein level at 
37 °C 
HEK293T cells, fluorescence microscopy: 
Redistribution of mutant plasma membrane protein 
from normal plasma membrane expression at 28 °C 
to strongly reduced plasma membrane protein at 37 
°C (this work) 
L994del deletion 
SHM + 
epilepsy (focal 
seizures) 
TM10 (Riant et al., 2010) (Spiller and Friedrich, 2014) 
X. laevis oocytes: no pump currents, normal overall 
protein expression but strongly reduced plasma 
membrane protein 
D999H missense mutation 
FHM, acute 
enzephalopathy C-Terminus 
(Fernandez et al., 
2008) 
(Merwick et al., 2013)
(Spiller and 
Friedrich, 2014) 
(Weigand et al., 
2014) 
X. laevis oocytes: strongly augmented voltage-
dependent decrease of pump currents at voltages 
below +20 mV and strongly altered K+ dependence of 
pump currents with increased apparent affinity for K+ 
below 20 mV and decreased apparent K+ affinity 
above 0 mV; strongly reduced voltage dependence 
with high an essentially voltage-insensitive rate 
constants of ouabain-sensitive Na+/Na+ exchange 
currents 
Sf9 cells: normal protein expression, no ouabain 
binding, no ATPase activity 
R1002Q missense mutation FHM C-Terminus (Jen et al., 2007) 
(Jen et al., 2007) 
(Poulsen et al., 
2010) 
HeLa cells: strongly reduced survival under ouabain 
challenge 
X. laevis oocytes: strong negative shift of voltage 
dependence of ouabain-sensitive Na+/Na+ exchange 
currents (↔decreased apparent affinity for 
extracellular Na+), inverted voltage dependence of 
rate constants of Na+/Na+ exchange currents (high at 
positive, low at negative voltages) 
K1003E missense mutation 
SHM + 
epilepsy (focal 
seizures) 
C-Terminus (Riant et al., 2010) (Spiller and Friedrich, 2014) 
X. laevis oocytes: normal K+ and voltage dependence 
of pump currents, negative shift of voltage 
dependence of ouabain-sensitive Na+/Na+ exchange 
currents (↔decreased apparent affinity for 
extracellular Na+), increase in rate constants of 
Na+/Na+ exchange currents above -40 mV 
R1007W missense mutation FHM C-Terminus (Pisano et al., 2013) (Pisano et al., 2013) 
X. laevis oocytes: electrophysiology: pump current 
amplitudes identical to WT, apparent K+ affinity 
above -60 mV increased compared to WT, positive 
shift of voltage dependence (↔increased apparent 
affinity for extracellular Na+)and changed voltage-
dependent kinetics of ouabain-sensitive Na+/Na+ 
exchange  currents (increase of rate constants) 
compared  to WT  
Y1009X non-sense mutation SHM C-Terminus 
(Gallanti et al., 2011) 
(Gallanti et al., 2008) 
(Spiller and 
Friedrich, 2014) 
X. laevis oocytes: no pump currents, normal overall 
protein expression but strongly reduced plasma 
membrane protein 
X1021R 
read-through 
mutation, C-
terminal 
extension by 
28 AA 
FHM C-Terminus Stop Codon 
(Jurkat-Rott et al., 
2004) 
(Tavraz et al., 2008)
(Toustrup-Jensen et 
al., 2014) 
X. laevis oocytes: reduced pump currents, strongly 
reduced turnover, normal overall and plasma 
membrane protein level, strongly increased apparent 
affinity for K+ from pump currents, drastically 
changed voltage dependence of ouabain-sensitive 
Na+/Na+ exchange currents compared to WT (strong 
negative shift↔decreased apparent affinity for 
extracellular Na+; strongly reduced equivalent 
charge), voltage dependence of rate constants from 
Na+/Na+ exchange currents opposite compared to WT 
COS cells: 28 amino acid extension in human 
ATP1A2 was inable to achieve stable cell lines under 
ouabain selection conditions, no ATP-dependent 
phosphorylation in transient transfection 
experiments; 28 amino acid extension in rat ATP1A1 
permitted generation of stable cell line under ouabain 
selection conditions, strongly reduced apparent Na+ 
affinity, similar apparent K+ affinity (but higher at 
high Na+), increased ATP and decreased vanadate 
sensitivity, reduced ouabain affinity compared to WT 
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